Serum estradiol and progesterone in the mid-luteal phase predict clinical pregnancy outcome in IVF/ICSI cycles

Sonntag, Barbara; Loebbecke, Kay C.; Nofer, Jerzy–Roch; Kiesel, L.; Greb, Robert R.

doi:10.3109/09513590.2013.797392

Cited by 24 publications

(20 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Investigators continue to seek for more sensitive and specific tests to predict cycle outcome and optimize treatment of couples undergoing IVF-ICSI and embryo transfer. In relation to this, the associations of elevated P-values and P-valuesoestradiol ratio on day of, or day after, HCG administration with cycle outcomes have been extensively investigated (Keltz et al, 2012;Liu et al, 2015;Santos-Ribeiro et al, 2014;Sonntag et al, 2013), whereas the relationship of HCG value after trigger and cycle outcomes was seldomly studied.…”

Section: Discussionmentioning

confidence: 99%

The value of HCG serum concentrations after trigger in predicting pregnancy and live birth rates in IVF–ICSI

Zhou¹,

Wang²,

Wang

et al. 2015

Reproductive BioMedicine Online

View full text Add to dashboard Cite

The aim of this study was to determine if an association existed between serum human chorionic gonadotrophin (HCG) level at 12 h after trigger and IVF and intracytoplasmic sperm (ICSI) treatment outcomes. Women undergoing initial IVF-ICSI and embryo transfer treatment using the long luteal phase gonadotrophin-releasing hormone agonist protocol between April 2012 and March 2013 for tubal factor were included (n = 699). In the clinical pregnancy group, HCG after trigger was significantly elevated (276.0 ± 5.1 versus 198.5 ± 6.1 mIU/mL; P < 0.001). The optimal cut-off value proposed by the receiver operating characteristic analysis (area under curve = 0.730) for HCG was 201.2 mIU/ml. Compared with the lower HCG group, the clinical pregnancy rate in the higher HCG group was increased in obese and non-obese patients (77.8% versus 57.3%, P < 0.05; 85.6% versus 53.0%, P < 0.01, respectively). Adjusted for age and body mass index, an increase of HCG was associated with a better IVF-ICSI treatment outcome (OR 4.39, 95% CI 2.99 to 6.45). Clinical pregnancy rate was significantly higher across increasing quartiles of HCG. An elevated level of serum HCG at 12 h after trigger was associated with a better IVF-ICSI outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

The value of HCG serum concentrations after trigger in predicting pregnancy and live birth rates in IVF–ICSI

Zhou¹,

Wang²,

Wang

et al. 2015

Reproductive BioMedicine Online

View full text Add to dashboard Cite

show abstract

“…Its role, however, remains controversial. Significant differences in luteal phase E 2 levels between conception and nonconception cycles have been described, and early luteal phase increases in E 2 have been observed in pregnant women (2)(3)(4). In contrast, other studies have failed to show a correlation between luteal phase E 2 levels and IVF cycle outcomes (5).…”

mentioning

confidence: 92%

“…OutcomeA: E 2 £50 pg/mL (n [ 660) B: E 2 51-100 pg/mL (n [ 472) C: E 2 >100 pg/mL (n[ 3,433) Note: Data are presented as number (percentage). a P< .05 between groups A and C. b P< .05 between groups B and C.Melnick.…”

mentioning

confidence: 99%

How low is too low? Cycle day 28 estradiol levels and pregnancy outcomes

Melnick

Pereira

Murphy

et al. 2016

Fertility and Sterility

View full text Add to dashboard Cite

“…Personalized luteal phase support Improvement in and individualization of COS regimens have been the subject of intensive research in the eld of ART, and patient-tailored COS has now become the state of the art. In contrast, the luteal phase of fresh IVF cycles has received little attention, and studies focusing on luteal phase characteristics following hCG triggering are scarce and have yielded con icting results (56)(57)(58)(59). Neither the updated Cochrane meta-analysis on LPS (7), nor the ESHRE guidelines (6) have included recommendations regarding patient monitoring during the luteal phase.…”

Section: Gnrh Agonistmentioning

confidence: 99%

A 10-Year Follow-Up on the Practice of Luteal Phase Support Using Worldwide Web-Based Surveys

Shoham

Leong

Weissman

2020

Preprint

View full text Add to dashboard Cite

BackgroundIt has been demonstrated that luteal phase support (LPS) is crucial in filling the gap between the disappearance of exogenously administered hCG for ovulation triggering and the initiation of secretion of endogenous hCG from the implanting conceptus. LPS has a pivotal role of in establishing and maintaining in vitro fertilization (IVF) pregnancies. Over the last decade, a plethora of studies bringing new information on many aspects of LPS have been published. Due to lack of consent between researchers and a dearth of robust evidence-based guidelines, we wanted to make the leap from the bench to the bedside, what are the common LPS practices in fresh IVF cycles compared to current evidence and guidelines? How has expert opinion changed over 10 years in light of recent literature?MethodsOver a decade (2009 - 2019), we conducted 4 web-based surveys on a large IVF-specialist website on common LPS practices and controversies. The self-report, multiple-choice surveys quantified results by annual IVF cycles.ResultsOn average, 303 IVF units responded to each survey, representing, on average, 231,000 annual IVF cycles. Most respondents in 2019 initiated LPS on the day of, or the day after egg collection (48.7% and 36.3%, respectively). In 2018, 72% of respondents administered LPS for 8-10 gestational weeks, while in 2019, 65% continued LPS until 10-12 weeks. Vaginal progesterone is the predominant delivery route; its utilization rose from 64% of cycles in 2009 to 74.1% in 2019. Oral P use has remained negligible; a slight increase to 2.9% in 2019 likely reflects dydrogesterone’s introduction into practice. E2 and GnRH agonists are rarely used for LPS, as is hCG alone, limited by its associated risk of ovarian hyperstimulation syndrome (OHSS). ConclusionsOur Assisted reproductive technology (ART)-community survey series gave us insights into physician views on using progesterone for LPS. Despite extensive research and numerous publications, evidence quality and recommendation levels are surprisingly low for most topics. Clinical guidelines use mostly low-quality evidence. There is no single accepted LPS protocol. Our study highlights the gaps between science and practice and the need for further LPS research, with an emphasis on treatment individualization.

show abstract

Serum estradiol and progesterone in the mid-luteal phase predict clinical pregnancy outcome in IVF/ICSI cycles

Cited by 24 publications

References 27 publications

The value of HCG serum concentrations after trigger in predicting pregnancy and live birth rates in IVF–ICSI

The value of HCG serum concentrations after trigger in predicting pregnancy and live birth rates in IVF–ICSI

How low is too low? Cycle day 28 estradiol levels and pregnancy outcomes

A 10-Year Follow-Up on the Practice of Luteal Phase Support Using Worldwide Web-Based Surveys

Contact Info

Product

Resources

About